The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Despite their clinical success, chimeric antigen receptor (CAR)-T cell therapies for B cell
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …

Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …

Insufficient reactivity against cells with low antigen density has emerged as an important
cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that …

Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Chimeric antigen receptor (CAR) T‐cell therapy represents a major advancement in
personalized cancer treatment. In this strategy, a patient's own T cells are genetically …

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed
and/or refractory pre–B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a …

Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM).
T cells can be genetically modified to express chimeric antigen receptors (CARs), which are …